Allogeneic hematopoietic cell transplantation ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Auteur(s) :
Hernández-Boluda, Juan Carlos [Auteur]
Universitat Politècnica de València = Universitad Politecnica de Valencia = Polytechnic University of Valencia [UPV]
Eikema, Diderik-Jan [Auteur]
Universiteit Leiden = Leiden University
Koster, Linda [Auteur]
Leiden University Medical Center [LUMC]
Kröger, Nicolaus [Auteur]
Universiteit Leiden = Leiden University
Robin, M. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
De Witte, Moniek [Auteur]
University Medical Center [Utrecht] [UMCU]
Finke, Jürgen [Auteur]
Finazzi, Maria Chiara [Auteur]
Università degli Studi di Milano = University of Milan [UNIMI]
Broers, Annoek [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Raida, Ludek [Auteur]
Schaap, Nicolaas [Auteur]
Radboud University Medical Center [Nijmegen]
Chiusolo, Patrizia [Auteur]
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Verbeek, Mareike [Auteur]
Technische Universität Munchen - Technical University Munich - Université Technique de Munich [TUM]
Hazenberg, Carin L. E. [Auteur]
University of Groningen [Groningen]
Halaburda, Kazimierz [Auteur]
Warsaw University of Technology [Warsaw]
Kulagin, Aleksandr [Auteur]
Pavlov First Saint Petersburg State Medical University [St. Petersburg]
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Gedde-Dahl, Tobias [Auteur]
Oslo University Hospital [Oslo]
Rabitsch, Werner [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Raj, Kavita [Auteur]
King's College Hospital [KCH]
Drozd-Sokolowska, Joanna [Auteur]
Medical University of Warsaw - Poland
Battipaglia, Giorgia [Auteur]
University of Naples Federico II = Università degli studi di Napoli Federico II
Polverelli, Nicola [Auteur]
Università degli Studi di Brescia = University of Brescia [UniBs]
Czerw, Tomasz [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Mclornan, Donal P. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Universitat Politècnica de València = Universitad Politecnica de Valencia = Polytechnic University of Valencia [UPV]
Eikema, Diderik-Jan [Auteur]
Universiteit Leiden = Leiden University
Koster, Linda [Auteur]
Leiden University Medical Center [LUMC]
Kröger, Nicolaus [Auteur]
Universiteit Leiden = Leiden University
Robin, M. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
De Witte, Moniek [Auteur]
University Medical Center [Utrecht] [UMCU]
Finke, Jürgen [Auteur]
Finazzi, Maria Chiara [Auteur]
Università degli Studi di Milano = University of Milan [UNIMI]
Broers, Annoek [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Raida, Ludek [Auteur]
Schaap, Nicolaas [Auteur]
Radboud University Medical Center [Nijmegen]
Chiusolo, Patrizia [Auteur]
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Verbeek, Mareike [Auteur]
Technische Universität Munchen - Technical University Munich - Université Technique de Munich [TUM]
Hazenberg, Carin L. E. [Auteur]
University of Groningen [Groningen]
Halaburda, Kazimierz [Auteur]
Warsaw University of Technology [Warsaw]
Kulagin, Aleksandr [Auteur]
Pavlov First Saint Petersburg State Medical University [St. Petersburg]
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Gedde-Dahl, Tobias [Auteur]
Oslo University Hospital [Oslo]
Rabitsch, Werner [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Raj, Kavita [Auteur]
King's College Hospital [KCH]
Drozd-Sokolowska, Joanna [Auteur]
Medical University of Warsaw - Poland
Battipaglia, Giorgia [Auteur]
University of Naples Federico II = Università degli studi di Napoli Federico II
Polverelli, Nicola [Auteur]
Università degli Studi di Brescia = University of Brescia [UniBs]
Czerw, Tomasz [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Mclornan, Donal P. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Titre de la revue :
Bone Marrow Transplantation
Nom court de la revue :
Bone Marrow Transplant
Date de publication :
2023-09-09
ISSN :
1476-5365
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Allogeneic hematopoietic cell transplantation (allo-HCT) is curative for myelofibrosis (MF) but assessing risk-benefit in individual patients is challenging. This complexity is amplified in CALR-mutated MF patients, as ...
Lire la suite >Allogeneic hematopoietic cell transplantation (allo-HCT) is curative for myelofibrosis (MF) but assessing risk-benefit in individual patients is challenging. This complexity is amplified in CALR-mutated MF patients, as they live longer with conventional treatments compared to other molecular subtypes. We analyzed outcomes of 346 CALR-mutated MF patients who underwent allo-HCT in 123 EBMT centers between 2005 and 2019. After a median follow-up of 40 months, the estimated overall survival (OS) rates at 1, 3, and 5 years were 81%, 71%, and 63%, respectively. Patients receiving busulfan-containing regimens achieved a 5-year OS rate of 71%. Non-relapse mortality (NRM) at 1, 3, and 5 years was 16%, 22%, and 26%, respectively, while the incidence of relapse/progression was 11%, 15%, and 17%, respectively. Multivariate analysis showed that older age correlated with worse OS, while primary MF and HLA mismatched transplants had a near-to-significant trend to decreased OS. Comparative analysis between CALR- and JAK2-mutated MF patients adjusting for confounding factors revealed better OS, lower NRM, lower relapse, and improved graft-versus-host disease-free and relapse-free survival (GRFS) in CALR-mutated patients. These findings confirm the improved prognosis associated with CALR mutation in allo-HCT and support molecular profiling in prognostic scoring systems to predict OS after transplantation in MF.Lire moins >
Lire la suite >Allogeneic hematopoietic cell transplantation (allo-HCT) is curative for myelofibrosis (MF) but assessing risk-benefit in individual patients is challenging. This complexity is amplified in CALR-mutated MF patients, as they live longer with conventional treatments compared to other molecular subtypes. We analyzed outcomes of 346 CALR-mutated MF patients who underwent allo-HCT in 123 EBMT centers between 2005 and 2019. After a median follow-up of 40 months, the estimated overall survival (OS) rates at 1, 3, and 5 years were 81%, 71%, and 63%, respectively. Patients receiving busulfan-containing regimens achieved a 5-year OS rate of 71%. Non-relapse mortality (NRM) at 1, 3, and 5 years was 16%, 22%, and 26%, respectively, while the incidence of relapse/progression was 11%, 15%, and 17%, respectively. Multivariate analysis showed that older age correlated with worse OS, while primary MF and HLA mismatched transplants had a near-to-significant trend to decreased OS. Comparative analysis between CALR- and JAK2-mutated MF patients adjusting for confounding factors revealed better OS, lower NRM, lower relapse, and improved graft-versus-host disease-free and relapse-free survival (GRFS) in CALR-mutated patients. These findings confirm the improved prognosis associated with CALR mutation in allo-HCT and support molecular profiling in prognostic scoring systems to predict OS after transplantation in MF.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-02-06T22:28:35Z
2024-03-20T10:06:44Z
2024-03-20T10:06:44Z